Overexpression of HIF-1α indicates a poor prognosis in tongue carcinoma and may be associated with tumour metastasis

Oncology Letters

Volumn 5, Issue 4, 2013, Pages 1285-1289

  Zheng, Yang ^a   Ni, Yanhong ^a   Huang, Xiaofeng ^a   Wang, Zhiyong ^a   Han, Wei ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Hypoxia inducible factor 1; Prognosis; Tongue carcinoma

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA;

ADULT; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TONGUE CARCINOMA;

EID: 84874436167     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1185     Document Type: Article

References (25)

1. Semenza GL and Wang GL: A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12: 5447-5454, 1992.
2. Iyer NV, Kotch LE, Agani F, et al: Cellular and developmental control of O2 homeostasis by hypoxia inducible factor 1 alpha. Genes Dev 12: 149-162, 1998.
3. Bruick RK and McKnight SL: A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294: 1337-1340, 2001
4. Wang GL, Jiang BH, Rue EA and Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92: 5510-5514, 1995.
5. Nakayama K, Kanzaki A, Hata K, Katabuchi H, Okamura H, Miyazaki K, Fukumoto M and Takebayashi Y: Hypoxia-inducible factor 1 alpha (HIF-1 alpha) gene expression in human ovarian carcinoma. Cancer Lett 176: 215-223, 2002.
6. Lee CH, Lee MK, Kang CD, Kim YD, Park do Y, Kim JY, Sol MY and Suh KS: Differential expression of hypoxia inducible factor-1 alpha and tumor cell proliferation between squamous cell carcinomas and adenocarcinomas among operable non-small cell lung carcinomas. J Korean Med Sci 18: 196-203, 2003.
7. Beasley NJ, Leek R, Alam M, Turley H, Cox GJ, Gatter K, Millard P, Fuggle S and Harris AL: Hypoxia-inducible factors HIF-1alpha and HIF-2 alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res 62: 2493-2497, 2002.
8. Bos R, Van Der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, Van Diest PJ and Van Der Wall E: Levels of hypoxia inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97: 1573-1581, 2003.
9. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
10. Zhang Q, Zhang ZF, Rao JY, et al: Treatment with siRNA and antisense oligonucleotides targeted to HIF-1 alpha induced apoptosis in human tongue squamous cell carcinomas. Int J Cancer 111: 849-857, 2004.
11. Cohen NA, Lai SY, Ziober AF and Ziober BL: Dysregulation of hypoxia inducible factor-1α in head and neck squamous cell carcinoma cell lines correlates with invasive potential. Laryngoscope 114: 418-423, 2004.
12. Liang X, Yang D, Hu J, Hao X, Gao J and Mao Z: Hypoxia inducible factor-α expression correlates with vascular endothelial growth factor-C expression and lymphangiogenesis/angiogenesis in oral squamous cell carcinoma. Anticancer Res 28: 1659-1666, 2008.
13. Yao H, Wang H, Zhang Z, Jiang BH, Luo J and Shi X: Sulforaphane inhibited expression of hypoxia-inducible factor-1α in human tongue squamous cancer cells and prostate cancer cells. Int J Cancer 123: 1255-1261, 2008.
14. Lin PY, Yu CH, Wang JT, et al: Expression of hypoxia-inducible factor-1 alpha is significantly associated with the progression and prognosis of oral squamous cell carcinomas in Taiwan. J Oral Pathol Med 37: 18-25, 2008.
15. Sasabe E, Zhou X, Li D, Oku N, Yamamoto T and Osaki T: The involvement of hypoxia-inducible factor-1α in the susceptibility to γ-rays and chemotherapeutic drugs of oral squamous cell carcinoma cells. Int J Cancer 120: 268-277, 2007.
16. Fillies T, Werkmeister R, van Diest PJ, Brandt B, Joos U and Buerger H: HIF-1α overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer 5: 84, 2005.
17. Roh JL, Cho KJ, Kwon GY, et al: The prognostic value of hypoxia markers in T2-staged oral tongue cancer. Oral Oncol 45: 63-68, 2009.
18. Winter SC, Shah KA, Han C, et al: The relation between hypoxiainducible factor (HIF)-1α and HIF-2α expression with anemia and outcome in surgically treated head and neck cancer. Cancer 107: 757-766, 2006.
19. Carroll VA and Ashcroft M: Role of hypoxia-inducible factor (HIF)-1α versus HIF-2α in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 66: 6264-6270, 2006.
20. Imamura T, Kikuchi H, Herraiz MT, et al: HIF-1α and HIF-2α have divergent roles in colon cancer. Int J Cancer 124: 763-771, 2009.
21. Kung AL, Zabludoff SD, France DS, et al: Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6: 33-43, 2004.
22. Li L, Lin X, Staver M, et al: Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res 65: 7249-7258, 2005.
23. Rapisarda A, Shoemaker RH and Melillo G: Targeting topoi-somerase I to inhibit hypoxia inducible factor 1. Cell Cycle 3: 172-175, 2004.
24. Raval RR, Lau KW, Tran MG, et al: Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25: 5675-86, 2005.
25. Scortegagna M, Martin RJ, Kladney RD, Neumann RG and Arbeit JM: Hypoxia-inducible factor-1α suppresses squamous carcinogenic progression and epithelial-mesenchymal transition. Cancer Res 69: 2638-2646, 2009.